Luc BUEE PhD Neurobiology

Course and current status

Luc Buée is a French scientist (CNRS Research Director), Director of the Jean-Pierre Aubert Research Centre and Head of the Inserm laboratory « Alzheimer & Tauopathies » at the University of Lille, France. His group is also part of the laboratory of Excellence (LabEx) DISTALZ and the Centre of Excellence in Neurodegenerative disorders (LiCEND).

He is currently the vice-president of the French Society for Neurosciences.

Luc Buée has a background in biochemistry, cell biology and neurosciences.

From 1989 to 1992, he prepared a PhD in the department of Geriatrics, Mount Sinai Medical Center, New York, USA under the supervision of Professor Howard Fillit and André Delacourte (Inserm, France), on “the role of proteoglycans in amyloidosis in Alzheimer's disease". He graduated from the University of Lille in October 1992

From 1992 to 1994, he was a post-doctoral fellow (funded by France Alzheimer Association) in the Inserm laboratory headed by Marc Mazzuca in Lille.

In October 1994, he has been appointed Research Associate by the CNRS (the French National Centre for scientific research). Since then, he has worked on Alzheimer disease and related disorders. He was  involved in the initial characterization of tau aggregates among neurodegenerative disorders. He has then developed experimental models to better understand the role of post-translational modifications in tau aggregation and tau secretion.

Since 2001, he is CNRS research director and heads a Inserm team dedicated to the understanding of neurodegenerative disorders and neuronal death on the hospital (CHU) campus at the University of Lille.

Scientific summary

His group is currently working on the pathophysiological consequences of neurofibrillary degeneration and their links to the amyloid pathology in Alzheimer disease. His group was/is also involved in different international consortia.

He has more than 200 publications referenced in PubMed.

1)    Dourlen P, Fernandez-Gomez F, Dupont C, Grenier-Boley B, Bellenguez C, Obriot H, Caillierez R, Sottejeau Y, Chapuis J, Bretteville A, Abdelfettah F, Delay C, Malmanche N, Soininen H, Hiltunen M, Galas MC, Amouyel P, Sergeant N, Buée L, Dermaut B, Lambert JC (2017) Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology. Mol Psychiatr, 22(6):874-883. doi: 10.1038/mp.2016.59.

2)    Laurent C, Dorothée G, Hunot S, Martin E, Monnet Y, Duchamp M, Duong Y, Légeron FP, Leboucher A, Burnouf S, Faivre E, Carvalho K, Caillierez R, Zommer N, Demeyer D, Jouy N, Sazdovitch V, Schraen-Maschke S, Delarasse C, Buée L, Blum D (2017) Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of Tauopathy. Brain, 140(Pt 1):184-200. doi: 10.1093/brain/aww270

3)    Marciniak E, Leboucher A, Caron E, Ahmed T, Tailleux A, Dumont J, Issad T, Gerhardt E, Pagesy P, Vileno M, Bournonville C, Hamdane M, Bantubungi K, Lancel S, Demeyer D, Eddarkaoui S, Vallez E, Vieau D, Humez S, Faivre E, Grenier-Boley , Outeiro TF, Staels B, Amouyel P, Balschun D, Buee L, Blum D (2017) Tau deletion promotes brain insulin resistance. J Exp Med, 214(8):2257-2269. doi: 10.1084/jem.20161731

4)    Šimić G, Leko MB, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, Silva R, Giovanni GD, Wischik C, Hof PR (2017) Monoaminergic Neuropathology in Alzheimer's disease. Prog Neurobiol, 151 : 101-138. http://dx.doi.org/10.1016/j.pneurobio.2016.04.001

5)    Huin V. Deramecourt V, Caparros-Lefebvre D, Maurage CA, Duyckaerts C, Kovari E, Pasquier F, Buée-Scherrer V, Labreuche J, Behal H, Buée L, Dhaenens CM, Sablonnière B (2016) The MAPT gene is differentially methylated in the progressive supranuclear palsy brain. Mov Disord, 31(12):1883-1890. doi: 10.1002/mds.26820.

6)    Kenisberg PA, Aquino JP, Bérard A, Gzil F, Andrieu S, Banerjee S, Brémond F, Buée L, Cohen-Mansfirld J, Mangialasche F, Platel H, Salmon E. Robert P (2016) Dementia beyond 2025: knowledge and uncertainties. Dementia (London), 15(1)6-21. doi: 10.1177/1471301215574785.

7)    Laurent C, Burnouf S, Ferry B, Batalha VL, Coelho JE, Baqi Y, Mariciniak E, Parrot S, Van der Jeugd A, Faivre E, Flaten V, Ledent C, D’Hooge R, Sergeant N, Hamdane M, Humez S, Müller CE, Lopes LV, Buée L, Blum D (2016) A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatr 21(1)97-107. doi: 10.1038/mp.2014.151.

8)    Papegaey A, Eddarkaoui S, Deramecourt V, Fernandez-Gomez FJ, Pantano P, Obriot H, Machala C, Anquetil V, Camuzat A, Brice A, Maurage CA, Le Ber I, Duyckaerts C, Buée L, Sergeant N, Buée-Scherrer V (2016) Reduced Tau protein expression is associated with frontotemporal dementia with progranulin mutation. Acta Neuropathol Comm, 4(1):74. doi: 10.1186/s40478-016-0345-0.

9)    Šimić G, Leko MB, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Danira Bažadona D, Buée L, De Silva R, Di Giovanni G, Wischik C, Hof PR (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 6(1):6. doi: 10.3390/biom6010006.

10) Tardivel M, Begard S, Bousset L, Dujardin S, Coens A, Melki R, Buée L, Colin M (2016) Tunneling nanotube-mediated neuron to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol Comm, 4:117 doi: 10.1186/s40478-016-0386-4.

11) Ahmed T, Blum D, Burnouf S, Demeyer D, Buée-Scherrer V, D’Hooge R, Buée L, Balschun D (2015) Rescue of impaired late-phase LTD in a tau transgenic mouse model. Neurobiol Aging, 36(2) 730-39.

12) Caparros-Lefebvre D, Golbe LI, Deramecourt V, Maurage CA, Huin V, Buée-Scherrer V, Obriot H, Sablonnière B, Caparros F, Buée L, Lees AJ (2015) A geographical cluster of progressive supranuclear palsy in Northern France. Neurology, 85(15) 1293-300.

13) Derisbourg M, Leghay C, Chiappetta G, Fernandez-Gomez FJ, Laurent C, Demeyer D, Carrier S, Buée-Scherrer V, Blum D, Vinh J, Sergeant N, Verdier Y, Buée L, Hamdane M (2015) Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep, 5:9659

14) Duyckaerts C, Braak H, Brion JP, Buée L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M, Uchihara T (2015) PART is part of Alzheimer disease. Acta Neuropathol, 129(5):749-56

15) Dujardin S, Lécolle K, Caillierez R, Bégard S, Zommer N, Lachaud C, Carrier S, Dufour N, Aurégan G, Winderickx J, Hantraye P, Déglon N, Colin M, Buée L (2014) Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun 2(1):14.

16) Kaffashian S, Tzourio C, Soumaré A, Dufouil C, Zhu Y, Crivello F, Maillard P, Schraen Maschke S, Mazoyer B, Buee L, and Debette S (2014) Plasma amyloid-ß and MRI markers of cerebral small vessel disease. Neurology, 83(22):2038-45

17) Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S, Schneider M, Hamdane M, Müller CE, Buée L, Blum D (2014) Beneficial effects of caffeine in a transgenic model of Alzheimer’s Disease-like Tau pathology. Neurobiol Aging, 35(9):2079-90.

18) Violet M, Delattre L, Tardivel M, Sultan A, Chauderlier A, Caillierez R, Talahari S, Nesslany F, Lefebvre B, Bonnefoy E, Buée L, Galas MC (2014) A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front Cell Neurosci. 2014 Mar 18;8:84.

19) Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D (2013) NMDA receptor dysfunction contributes to impaired BDNF-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell, 12(1): 11-23.

20) Caillierez R, Bégard S, Lécolle K, Deramecourt V, Zommer N, Dujardin S, Loyens A, Dufour N, Aurégan G, Winderickx J, Hantraye P, Déglon N, Buée L, Colin M (2013) Lentiviral delivery of the human wild-type Tau protein mediates a slow and progressive neurodegenerative Tau pathology in the rat brain. Mol Ther 21(7):1358-68

21) Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S, Demeyer D, Caillierez R, Zommer N, Vallez E, Bantubungi K, Breton C, Pigny P, Buée-Scherrer V, Staels B, Hamdane M, Tailleux A, Buée L, Blum D (2013) Detrimental Effects of Diet-Induced Obesity on τ Pathology Is Independent of Insulin Resistance in τ Transgenic Mice. Diabetes, 62(5):1681-8.

22) Brouillette J, Caillierez R, Zommer N, Alves-Pires C, Benilova I, Blum D, De Strooper B, Buée L (2012) Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-ß1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci 32(23):7852–7861

23) Le Freche H, Brouillette J, Fernandez-Gomez FJ, Patin P, Caillierez R, Zommer N, Sergeant N, Lebuffe G, Blum D, Buée L (2012) Tau phosphorylation and sevoflurane anesthesia: a link to postoperative cognitive impairment. Anesthesiology 116(4):779-787

24) Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen S, Blum D, Buée L (2012) Targeting phospho-Ser422 by active immunotherapy in the Thy-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9(4): 397-405

25) Smith PY, Delay C, Girard J, Papon MA, Planel E, Sergeant N, Buée L, Hébert SS (2011) MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet 20(20):4016-24

26) Sultan A, Nesslany F, Violet M, Bégard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S, Colin M, Bonnefoy E, Buée L, Galas MC (2011) Nuclear Tau : a key player in neuronal DNA protection. J Biol Chem, 286(6): 4566-4575

27) Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean ME, Humez S, Balschun D, Blum D, Buée L, D'Hooge R (2011) Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem, 95(3) : 296-304

28) Hébert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silahtaroglu AN, Sergeant N, Buée L, De Strooper B (2010) Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet, 19(20):3959-69.

29) Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alpérovitch A, Buée L, Amouyel P (2009) Association of plasma Ab with risk of dementia: the prospective 3C-study. Neurology, 73 :847-53.

30) Schindowski K, Bretteville A, Leroy K, Bégard S, Brion JP, Hamdane M, Buée L (2006) Alzheimer disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol, 169(2) 599-616.

Image d’exemple